About
Copy Link
Titles
Research Assistant 2 HSS
Departments & Organizations
Research
Copy Link
Research at a Glance
Yale Co-Authors
Frequent collaborators of Mark Dias's published research.
Publications Timeline
A big-picture view of Mark Dias's research output by year.
Richard Carson, PhD
David Matuskey, MD
Jean-Dominique Gallezot, PhD
Mika Naganawa, PhD
Nabeel Nabulsi, PhD
Shannan Henry
14Publications
475Citations
Publications
2026
Lower synaptic density in mood circuitry underlies depression in Parkinson’s disease
Cayir S, Naganawa M, Volpi T, Sadabad F, Dias M, Yang Y, Elliott S, Ansari M, Elshahat A, Pittman B, Esterlis I, Nabulsi N, Huang Y, Sanacora G, Comley R, Finnema S, Carson R, Tinaz S, Matuskey D, Holmes S. Lower synaptic density in mood circuitry underlies depression in Parkinson’s disease. Brain Communications 2026, 8: fcag136. PMID: 42109687, PMCID: PMC13152014, DOI: 10.1093/braincomms/fcag136.Peer-Reviewed Original ResearchAltmetricConceptsAnterior cingulate cortexDepressive symptomsSynaptic densityMood-related brain regionsSeverity of depressive symptomsParkinson's diseaseDorsolateral prefrontal cortexSymptoms of depressionPrefrontal cortexCingulate cortexComorbid depressionBrain regionsBinding potentialParkinson's disease patientsDepressionSynaptic plasticitySynaptic vesicle protein 2AMoodMotor symptomsDLPFCAmygdalaHealthy controlsHippocampusEvaluation of interventionsCortexSV2A PET reveals synaptic density loss in experimental autoimmune encephalomyelitis and in a pilot multiple sclerosis study
Chia P, Toyonaga T, Tong J, Le H, Dias M, Boyle A, Raymond R, Longbrake E, Huang Y, Carson R, Airas L, Vasdev N, Chen M, Zheng C. SV2A PET reveals synaptic density loss in experimental autoimmune encephalomyelitis and in a pilot multiple sclerosis study. Proceedings Of The National Academy Of Sciences Of The United States Of America 2026, 123: e2517709123. PMID: 41774796, PMCID: PMC12974510, DOI: 10.1073/pnas.2517709123.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsExperimental autoimmune encephalomyelitisMultiple sclerosisAutoimmune encephalomyelitisPET imagingSpinal cordExperimental autoimmune encephalomyelitis miceAge-matched healthy controlsQuantitative biomarkersLumbar spinal cordRegional distribution volumesDensity in vivoCross-species validationSynaptic vesicle glycoprotein 2APET findingsTracer uptakeSV2A bindingSynaptic pathologyHealthy controlsDisease progressionMouse modelMS patientsPathological featuresDistribution volumeMultiple Sclerosis StudySV2A levels
2025
Measuring Dopamine Transporter Availability and Synaptic Density in Parkinson's Disease: A Dual‐Tracer Positron Emission Tomography Imaging Study
Sadabad F, Volpi T, Honhar P, Tinaz S, Dias M, Toyonaga T, Naganawa M, Gallezot J, Yang Y, Ibrahim W, Pittman B, Cayir S, Radhakrishnan R, Angarita G, Holmes S, Comley R, Carson R, Finnema S, Matuskey D. Measuring Dopamine Transporter Availability and Synaptic Density in Parkinson's Disease: A Dual‐Tracer Positron Emission Tomography Imaging Study. Movement Disorders 2025, 40: 2678-2687. PMID: 41040062, DOI: 10.1002/mds.70041.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsC-UCB-JDopamine transporterHealthy controlsVentral striatumDisease stageSubstantia nigraSynaptic densityParkinson's diseaseDopamine transporter availabilityPositron emission tomography imaging studiesSynaptic vesicle glycoprotein 2AAssessment of synaptic densityDopaminergic denervationBetween-group differencesTransporter availabilityBinding potentialNigrostriatal regionDisease durationDual-tracerImaging studiesPatientsPET imagingPresynaptic degenerationPD patientsDopamineCarotid Artery Image-Derived Blood Time-Activity Curves on the NeuroEXPLORER: Initial Multitracer Validation Against Arterial Sampling.
Volpi T, Gallezot J, Henry S, Dias M, Khattar N, Toyonaga T, Fontaine K, Mulnix T, Zhang J, Guo L, Gravel P, Radhakrishnan R, Hillmer A, Matuskey D, Carson R. Carotid Artery Image-Derived Blood Time-Activity Curves on the NeuroEXPLORER: Initial Multitracer Validation Against Arterial Sampling. Journal Of Nuclear Medicine 2025, 66: 1993-2001. PMID: 41043999, PMCID: PMC12676648, DOI: 10.2967/jnumed.125.270414.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsArea under the curveCommon carotidTime-activity curvesLate area under the curveMethods:Carotid arteryRegions-of-interestResults:Blood samplesPartial volume effectsImage-derived input functionArterial blood samplesArterial input functionAlternative to arterial blood samplingBlood time-activity curvesPET kinetic modelingGold standardInput functionBackground activityArterial samplesCarotidBrain-dedicated PET scannersBrain PET
2024
Clinical correlates of dopamine transporter availability in cross-sectional and longitudinal studies with [18F]FE-PE2I PET: independent validation with new insights
Honhar P, Sadabad F, Tinaz S, Gallezot J, Dias M, Naganawa M, Yang Y, Henry S, Hillmer A, Gao H, Najafzadeh S, Comley R, Nabulsi N, Huang Y, Finnema S, Carson R, Matuskey D. Clinical correlates of dopamine transporter availability in cross-sectional and longitudinal studies with [18F]FE-PE2I PET: independent validation with new insights. Brain Communications 2024, 6: fcae345. PMID: 39429243, PMCID: PMC11487911, DOI: 10.1093/braincomms/fcae345.Peer-Reviewed Original ResearchCitationsConceptsDAT availabilityMotor severitySubstantia nigraDopamine transporter availabilityClinical trials of Parkinson's diseaseParkinson's diseaseLongitudinal studyTracking longitudinal changesClinical correlatesVentral striatumTransporter availabilityNigrostriatal regionParkinson's disease patientsPutamenMotor severity scoresAssociated with increasesSubstantiaDATLongitudinal changesTremor scoreNegative associationNigraSubstantia nigra of Parkinson's disease patientsTremor severityPET biomarkersAuthor Correction: Synaptic loss and its association with symptom severity in Parkinson’s disease
Holmes S, Honhar P, Tinaz S, Naganawa M, Hilmer A, Gallezot J, Dias M, Yang Y, Toyonaga T, Esterlis I, Mecca A, Van Dyck C, Henry S, Ropchan J, Nabulsi N, Louis E, Comley R, Finnema S, Carson R, Matuskey D. Author Correction: Synaptic loss and its association with symptom severity in Parkinson’s disease. Npj Parkinson's Disease 2024, 10: 55. PMID: 38472206, PMCID: PMC10933370, DOI: 10.1038/s41531-024-00674-6.Peer-Reviewed Original ResearchCitationsSynaptic loss and its association with symptom severity in Parkinson’s disease
Holmes S, Honhar P, Tinaz S, Naganawa M, Hilmer A, Gallezot J, Dias M, Yang Y, Toyonaga T, Esterlis I, Mecca A, Van Dyck C, Henry S, Ropchan J, Nabulsi N, Louis E, Comley R, Finnema S, Carson R, Matuskey D. Synaptic loss and its association with symptom severity in Parkinson’s disease. Npj Parkinson's Disease 2024, 10: 42. PMID: 38402233, PMCID: PMC10894197, DOI: 10.1038/s41531-024-00655-9.Peer-Reviewed Original ResearchCitationsAltmetricConceptsSynaptic density lossPositron emission tomographyBinds to synaptic vesicle glycoprotein 2AAssociated with symptom severityParkinson's diseaseHigh-resolution positron emission tomographySynaptic vesicle glycoprotein 2ADuration of illnessPositron emission tomography scanBrain perfusionIllness durationSymptom severitySeverity of symptomsHC groupSubstantia nigraSynaptic densityLiving brainPD individualsClinical insightsDensity lossPD patientsEmission tomographyBrainSynaptic lossSynapse lossFirst-in-Human Study of 18F-SynVesT-2: An SV2A PET Imaging Probe with Fast Brain Kinetics and High Specific Binding
Drake L, Wu Y, Naganawa M, Asch R, Zheng C, Najafzadeh S, Pracitto R, Lindemann M, Li S, Ropchan J, Labaree D, Emery P, Dias M, Henry S, Nabulsi N, Matuskey D, Hillmer A, Gallezot J, Carson R, Cai Z, Huang Y. First-in-Human Study of 18F-SynVesT-2: An SV2A PET Imaging Probe with Fast Brain Kinetics and High Specific Binding. Journal Of Nuclear Medicine 2024, 65: jnumed.123.266470. PMID: 38360052, PMCID: PMC10924160, DOI: 10.2967/jnumed.123.266470.Peer-Reviewed Original ResearchCitationsAltmetricConceptsFirst-in-human studyPlasma free fractionTime-activity curvesCentrum semiovaleNonhuman primate's resultsFirst-in-humanFree fractionNondisplaceable binding potentialRegional time-activity curvesLow nonspecific uptakeRegional distribution volumesHigh-resolution research tomograph scannerTest-retest reproducibilityCerebral blood flowSynaptic vesicle glycoprotein 2AHealthy volunteersArterial input functionNonspecific uptakePET imaging probeDistribution volumeSynapse densityIndividual MR imagesHighest specific bindingMR imagingPET imaging
2023
The regional pattern of age-related synaptic loss in the human brain differs from gray matter volume loss: in vivo PET measurement with [11C]UCB-J
Toyonaga T, Khattar N, Wu Y, Lu Y, Naganawa M, Gallezot J, Matuskey D, Mecca A, Pittman B, Dias M, Nabulsi N, Finnema S, Chen M, Arnsten A, Radhakrishnan R, Skosnik P, D’Souza D, Esterlis I, Huang Y, van Dyck C, Carson R. The regional pattern of age-related synaptic loss in the human brain differs from gray matter volume loss: in vivo PET measurement with [11C]UCB-J. European Journal Of Nuclear Medicine And Molecular Imaging 2023, 51: 1012-1022. PMID: 37955791, PMCID: PMC12701775, DOI: 10.1007/s00259-023-06487-8.Peer-Reviewed Original ResearchCitationsAltmetricConceptsSynaptic densityAge-related decreaseMagnetic resonance imagingBlood flowAge-related synaptic lossGray matter volume lossSynaptic density lossPositron emission tomography (PET) ligandSynaptic vesicle glycoprotein 2AVivo PET measurementsMedial occipital cortexGray matter volumeAge-related neurodegenerationGray matter regionsCognitive normal subjectsAge-related changesSynaptic lossNerve terminalsWide age rangeOccipital cortexTomography ligandNormal subjectsGM volumeAge-related functional lossesMatter volume
2022
Neurotransmitter transporter occupancy following administration of centanafadine sustained-release tablets: A phase 1 study in healthy male adults
Matuskey D, Gallezot J, Nabulsi N, Henry S, Torres K, Dias M, Angarita G, Huang Y, Shoaf S, Carson R, Mehrotra S. Neurotransmitter transporter occupancy following administration of centanafadine sustained-release tablets: A phase 1 study in healthy male adults. Journal Of Psychopharmacology 2022, 37: 164-171. PMID: 36515395, PMCID: PMC9912308, DOI: 10.1177/02698811221140008.Peer-Reviewed Original ResearchCitationsAltmetric
Get In Touch
Copy Link
Contacts
Email